Home > Insider Trading > Filing (0001615774-18-006729)

Filing Details

Accession Number:: 0001615774-18-006729
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-07-20 16:50:19
Reporting Period:: 2018-07-20

Accepted Time:: 2018-07-20 16:50:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658247	Crinetics Pharmaceuticals Inc.	CRNX	()	1231

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1618788	Vivo Capital Fund Viii, L.p.	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1618789	Vivo Capital Viii, Llc	C/O Vivo Capital Llc 505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1628048	Vivo Capital Surplus Fund Viii, L.p.	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1674712	Vivo Capital, Llc	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1726403	Vivo Opportunity Fund, L.p.	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No
1728970	Vivo Opportunity, Llc	505 Hamilton Avenue, Suite 207 Palo Alto CA 94301	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-07-20	2,560,613	$0.00	2,560,613	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	353,590	$0.00	353,590	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	413,040	$0.00	2,973,653	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	57,035	$0.00	410,625	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	51,686	$17.00	3,025,339	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	7,137	$17.00	417,762	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	141,177	$17.00	141,177	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2018-07-20	153,180	$20.73	294,357	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2018-07-20	8,424,416	$0.00	2,560,613	$0.00
Common Stock	Series A Preferred Stock	Disposition	2018-07-20	1,163,311	$0.00	353,590	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-07-20	1,358,903	$0.00	413,040	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-07-20	187,648	$0.00	57,035	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The shares of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series A Preferred Stock and Series B Preferred Stock had no expiration date.
These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").
These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").
These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").
Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. Vivo Capital LLC is the management company of Vivo LLC. The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the Issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
Vivo Opportunity, LLC is the general partner of VOF. Vivo Capital LLC is the management company of Vivo Opportunity, LLC. The voting members of Vivo Opportunity, LLC are Frank Kung, Albert Cha, Shan Fu, Gaurav Aggarwal and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.25 to $24.5, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.